Home > Press > Abraxis BioScience Announces Date for 2009 First Quarter Financial Results and Investor Conference Call
![]() |
Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2009 first quarter financial results before the market opens on Thursday, May 7, 2009. The company also said that senior management will host an investor conference call the same day, Thursday, May 7, 2008, at 8:30 a.m. PT/11:30 a.m. ET to review the company's financial results.
The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com. The call will also be archived and accessible at both sites for six months.
####
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab™ platform. The first FDA approved product to use this nab™ platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABBI.
For more information, please click here
Contacts:
Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman
Director, Investor Relations & Corporate Communications
310-405-7522
or
Pondel Wilkinson Inc.
Rob Whetstone
310-279-5963
Copyright © Business Wire 2009
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |